Organovo Holdings, Inc. - Common Stock (ONVO)
0.2722
-0.1317 (-32.61%)
Organovo Holdings is a biotechnology company specializing in 3D bioprinting technologies with a focus on creating functional human tissues for medical research and therapeutic applications
By leveraging its innovative platform, the company aims to revolutionize the fields of drug discovery and regenerative medicine by enabling the generation of biologically relevant tissues that can be used for testing pharmaceutical compounds, understanding disease mechanisms, and potentially advancing personalized medicine solutions. Their work holds the promise of improving patient outcomes by providing more accurate models for studying human biology and disease.
Previous Close | 0.4039 |
---|---|
Open | 0.3246 |
Bid | 0.2600 |
Ask | 0.2670 |
Day's Range | 0.2531 - 0.3330 |
52 Week Range | 0.3154 - 1.830 |
Volume | 3,688,709 |
Market Cap | 2.37M |
PE Ratio (TTM) | -0.3202 |
EPS (TTM) | -0.8 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 21,640,400 |
News & Press Releases
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top gainers and losers in today's session.
Via Chartmill · March 19, 2025
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.
Via Chartmill · March 19, 2025
Via Benzinga · March 19, 2025
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Via Chartmill · March 19, 2025
Via Benzinga · March 19, 2025
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock that will become effective at 5:00 p.m. Eastern Time on Thursday, March 20, 2025. Organovo’s common stock will commence trading on a reverse stock split-adjusted basis at the opening of the market on Friday, March 21, 2025.
By Organovo, Inc. · Via GlobeNewswire · March 19, 2025

BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the “Effective Date”). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date.
By Matinas BioPharma Holdings, Inc. · Via GlobeNewswire · March 11, 2025

SAN DIEGO, March 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced it has issued additional shares in conjunction with warrant exercises by investors and at-the-market stock sales. An additional 2,967,144 shares of common stock of the Company have been issued. The shares of common stock issuable upon exercise of the outstanding warrants were registered pursuant to a registration statements that was declared effective on May 8, 2024. The aggregate gross proceeds from the exercise of the existing warrants and at-the-market stock sales are expected to total approximately $2.3 million, before deducting financial advisory fees and commissions. After giving effect to the issuance of these additional shares, the Company has 20,421,617 shares of outstanding common stock.
By Organovo, Inc. · Via GlobeNewswire · March 6, 2025

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · February 26, 2025

These stocks have an unusual volume in today's session
Via Chartmill · February 26, 2025

Enveric Biosciences (NASDAQ: ENVB) Secures Patent for EVM401 Series, Advancing Neuropsychiatric Treatments Small-cap biotech stocks continue to push boundaries, with Enveric Biosciences (NASDAQ: ENVB) securing U.S. Patent No. 12,195,439 for its EVM401 Series, a novel class of non-hallucinogenic mescaline derivatives designed for addiction and neuropsychiatric disorders . This milestone solidifies Enveric’s standing in the neuroplastogen therapeutics sector, a rapidly emerging field within mental health treatment. The EVM401 compounds exhibit unique brain receptor modulation, potentially offering new alternatives for patients with limited therapeutic options.
Via AB Newswire · February 26, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · February 25, 2025

Let's dive into the action on the US markets on Tuesday. Here are the most active stocks that are driving the market today.
Via Chartmill · February 25, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · February 25, 2025

Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.
Via Chartmill · February 25, 2025

Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · February 25, 2025

Via Benzinga · February 25, 2025

Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR program, including FXR314.
Via Benzinga · February 25, 2025

SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today announced that Eli Lilly and Company (NYSE:LLY) (“Lilly”) will acquire Organovo’s FXR program, including its lead asset, FXR314.
By Organovo, Inc. · Via GlobeNewswire · February 25, 2025

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that it had appointed Norman Staskey as Chief Financial Officer.
By Organovo, Inc. · Via GlobeNewswire · January 6, 2025

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its oral presentation of its lead clinical stage drug FXR314 by Dr. Eric Lawitz of the Texas Liver Institute and the University of Texas Health San Antonio was featured at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The meeting was held November 15-19, 2024 in San Diego, California.
By Organovo, Inc. · Via GlobeNewswire · November 20, 2024

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its lead clinical stage drug, FXR314 will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, by Dr. Eric Lawitz of the Texas Liver Institute, will describe the findings from the FXR314 Phase 2 MASH study. The meeting will be held November 15-19, 2024 in San Diego, California.
By Organovo, Inc. · Via GlobeNewswire · November 13, 2024